Ongoing investigational trials using mRNA vaccines (eg, those targeting IDH1 mutations or multiple TAAs) are currently being conducted for early-phase evaluation (eg, NCT03893903).184 The use of GBM-associated surface antigens to identify novel treatment targets for GBM via an mRNA approach has been revealed. The gene discussed is IDH1; the disease is glioblastoma.